Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

How many rare diseases are there?

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 19, 77-78 (2020)

doi: https://doi.org/10.1038/d41573-019-00180-y

Acknowledgements

NIH grant R24 OD011883 provided funding to M.H., C.M., P.N.R., N.V., J.M., N.H., D.U. and M.P.H. NIH grants U24 CA224370, U24 TR002278, U01 CA239108 and P30 CA118100 provided funding to G.B., C.B., C.M., T.I.O. and P.N.R. The Angela Wright Bennett Foundation and the McCusker Charitable Foundation support Gareth Baynam. OMIM is funded by NIH grant U41 HG006627.

Updates & Corrections

  • Correction 14 July 2023: An error in the spelling of Courtney Thaxton's name has been corrected.

References

  1. Haendel, M. A., Chute, C. G. & Robinson, P. N. Classification, ontology, and precision medicine. N. Engl. J. Med. 379, 1452–1462 (2018).

    Article  PubMed  Google Scholar 

  2. Haendel, M. A. et al. A census of disease ontologies. Annu. Rev. Biomed. Data Sci. 1, 305–331 (2018).

    Article  Google Scholar 

  3. Oprea, T. I. et al. Unexplored therapeutic opportunities in the human genome. Nat. Rev. Drug Discov. 17, 317-332 (2018).

    Article  PubMed  Google Scholar 

  4. Mungall, C. J. et al. k-BOOM: a Bayesian approach to ontology structure inference, with applications in disease ontology construction. bioRxiv 048843; doi: https://doi.org/10.1101/048843 (2019).

  5. Tambuyzer, E. et al. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nat. Rev. Drug Discov. 19, 93–111 (2020).

    PubMed  Google Scholar 

Download references

Supplementary Information

  1. Supplementary Box 1

Competing Interests

M.H., J.M. and T.G. are co-founders of Pryzm Health. T.G. has received funding or consulted for Johnson & Johnson. A.H. owns stock in Blade Therapeutics. T.I.O. has received honoraria or consulted for Abbott, AstraZeneca, Chiron, Genentech, Infinity Pharmaceuticals, Merz Pharmaceuticals, Merck Darmstadt, Mitsubishi Tanabe, Novartis, Ono Pharmaceuticals, Pfizer, Roche, Sanofi and Wyeth.

Nature Careers

Jobs

  • Postdoctoral Position

    We are seeking highly motivated and skilled candidates for postdoctoral fellow positions

    Boston, Massachusetts (US)

    Boston Children's Hospital (BCH)

  • Qiushi Chair Professor

    Distinguished scholars with notable achievements and extensive international influence.

    Hangzhou, Zhejiang, China

    Zhejiang University

  • ZJU 100 Young Professor

    Promising young scholars who can independently establish and develop a research direction.

    Hangzhou, Zhejiang, China

    Zhejiang University

  • Head of the Thrust of Robotics and Autonomous Systems

    Reporting to the Dean of Systems Hub, the Head of ROAS is an executive assuming overall responsibility for the academic, student, human resources...

    Guangzhou, Guangdong, China

    The Hong Kong University of Science and Technology (Guangzhou)

  • Head of Biology, Bio-island

    Head of Biology to lead the discovery biology group.

    Guangzhou, Guangdong, China

    BeiGene Ltd.

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links